Cargando…
Circulating biomarkers in malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage. Radiological screenings have not proven to be effective and also pathological diagnosis may be challenging. In the era of precision...
Autores principales: | Viscardi, Giuseppe, Di Natale, Davide, Fasano, Morena, Brambilla, Marta, Lobefaro, Riccardo, De Toma, Alessandro, Galli, Giulia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400735/ https://www.ncbi.nlm.nih.gov/pubmed/36046389 http://dx.doi.org/10.37349/etat.2020.00028 |
Ejemplares similares
-
How I treat malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020) -
SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020) -
Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014) -
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation
por: Ferrari, Luca, et al.
Publicado: (2020) -
Management of Pleural Effusion Secondary to Malignant Mesothelioma
por: Musso, Valeria, et al.
Publicado: (2021)